Compare CBZ & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CBZ | PGEN |
|---|---|---|
| Founded | 1987 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.4B |
| IPO Year | 1996 | 2013 |
| Metric | CBZ | PGEN |
|---|---|---|
| Price | $32.94 | $4.17 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $41.33 | $8.33 |
| AVG Volume (30 Days) | 804.2K | ★ 3.6M |
| Earning Date | 04-29-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 134.62 | N/A |
| EPS | ★ 1.83 | N/A |
| Revenue | ★ $922,003,000.00 | $230,981,000.00 |
| Revenue This Year | $3.92 | $1,115.92 |
| Revenue Next Year | $4.12 | $81.04 |
| P/E Ratio | $17.82 | ★ N/A |
| Revenue Growth | ★ 7.79 | N/A |
| 52 Week Low | $24.29 | $1.23 |
| 52 Week High | $77.91 | $5.47 |
| Indicator | CBZ | PGEN |
|---|---|---|
| Relative Strength Index (RSI) | 67.77 | 56.45 |
| Support Level | $24.87 | $3.97 |
| Resistance Level | $54.79 | $4.40 |
| Average True Range (ATR) | 1.33 | 0.22 |
| MACD | 0.42 | 0.00 |
| Stochastic Oscillator | 85.38 | 64.04 |
CBIZ Inc through its subsidiaries provides professional services advisors to middle-market businesses and organizations nationwide. Its business units have been aggregated into three practice groups: Financial Services, Benefits and Insurance Services, and National Practices. The company provides its services to various industries such as Banking & Financial Services, Commercial Real Estate, Construction, Health Care Manufacturing & Distribution NFP & Education, Private Client Services, Professional Services, Public Sector, and Technology & Life Sciences. It derives the maximum of its revenues from the Financial Services segment and geographically from the United States.
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.